A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients
by Scagliotti, Giorgio V. (Author)
, Moro-Sibilot, Denis (Author)
, Kollmeier, Jens (Author)
, Favaretto, Adolfo (Author)
, Cho, Eun Kyung (Author)
, Grosch, Heidrun (Author)
, Kimmich, Martin (Author)
, Girard, Nicolas (Author)
, Tsai, Chun-Ming (Author)
, Hsia, Te-Chun (Author)
, Brighenti, Matteo (Author)
, Schumann, Christian (Author)
, Wang, Xuejing Aimee (Author)
, Wijayawardana, Sameera R. (Author)
, Gruver, Aaron M. (Author)
, Wallin, Johan (Author)
, Mansouri, Kambiz (Author)
, Wacheck, Volker (Author)
, Chang, Gee-Chen (Author)
,
Call Number:
Loading…
Located:
Loading…
Article (Journal)
Online Resource